A carregar...
Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status
IMPORTANCE: Imatinib introduced a paradigm shift in the treatment of patients with chronic myeloid leukemia (CML), allowing a lifespan that is almost comparable to the general population. However, the health care expenditures associated with imatinib have increased steadily since its introduction in...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7042837/ https://ncbi.nlm.nih.gov/pubmed/31999305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6390 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|